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SUMMARY
Background
Evidence suggests that the gut microbiota play an important role in gastrointestinal
problems.
Aim
To give clinicians a practical reference guide on the role of speciﬁed probiotics
in managing particular lower gastrointestinal symptoms/problems by means of a
systematic review-based consensus.
Methods
Systematic literature searching identiﬁed randomised, placebo-controlled trials in
adults; evidence for each symptom/problem was graded and statements developed
(consensus process; 10-member panel). As results cannot be generalised between
different probiotics, individual probiotics were identiﬁed for each statement.
Results
Thirty seven studies were included; mostly on irritable bowel syndrome [IBS; 19 stud-
ies; treatment responder rates: 18–80% (speciﬁc probiotics), 5–50% (placebo)] or anti-
biotic-associated diarrhoea (AAD; 10 studies). Statements with 100% agreement and
‘high’ evidence levels indicated that: (i) speciﬁc probiotics help reduce overall symp-
tom burden and abdominal pain in some IBS patients; (ii) in patients receiving anti-
biotics/Helicobacter pylori eradication therapy, speciﬁed probiotics are helpful as
adjuvants to prevent/reduce the duration/intensity of AAD; (iii) probiotics have
favourable safety in patients in primary care. Items with 70–100% agreement and
‘moderate’ evidence were: (i) speciﬁc probiotics help relieve overall symptom burden
in some patients with diarrhoea-predominant IBS, and reduce bloating/distension and
improve bowel movement frequency/consistency in some IBS patients and (ii) with
some probiotics, improved symptoms have led to improvement in quality of life.
Conclusions
Speciﬁed probiotics can provide beneﬁt in IBS and antibiotic-associated diarrhoea;
relatively few studies in other indications suggested beneﬁts warranting further
research. This study provides practical guidance on which probiotic to select for a
speciﬁc problem.
Aliment Pharmacol Ther 2013; 38: 864–886
ª 2013 John Wiley & Sons Ltd
doi:10.1111/apt.12460
864
Alimentary Pharmacology and Therapeutics
INTRODUCTION
Gastrointestinal (GI) problems are a major reason for
consultation.1 Symptom management of GI problems
often begins in primary care with adjustment of lifestyle
factors that may cause or worsen symptoms, such as
diet.2 Pharmacological treatments for patients with func-
tional GI disorders (FGID) have limited efﬁcacy and
may cause side effects.3, 4 Given that changes in the gut
microbiota have been implicated in the pathogenesis of
GI disorders [such as irritable bowel syndrome (IBS)],5–8
there is growing interest in therapies that might inﬂu-
ence these changes, such as probiotics.
Probiotics are deﬁned as ‘live microorganisms which
when administered in adequate amounts confer a health
beneﬁt on the host’.9 These are distinct from prebiotics
(dietary substances such as indigestible oligosaccharides
that provide a health beneﬁt by selectively promoting the
growth of beneﬁcial bacteria in the gut) and synbiotics
(products containing a synergistic combination of pre-
biotics and probiotics). The remainder of this article will
focus on probiotics. Despite their long history, wide
availability and substantial publication record, the clinical
role of probiotics has, in general, been inadequately char-
acterised and remains ill-deﬁned. Attempts to summarise
probiotic research are complicated by the wide variety of
probiotic strains that are available, as results obtained
with one strain are not generalisable to others.10 The
range of different formulations (capsules, sachets,
yoghurts and fermented milks or fruit drinks), the dose
and the presence of supporting substrates add further
sources of variation.11–13 Effects, moreover, may be dif-
ferent according to age and health status of the target
group.14, 15
Many gastroenterologists recommend probiotics,16, 17
and primary care physicians are increasingly confronted
with questions about the suitability (or otherwise) of
probiotics, but their familiarity with probiotics is lim-
ited.18, 19 All clinicians are faced with an increasingly
broad range of products, and deciding whether or not to
recommend one of these to a particular patient is a
major challenge. At the same time, the public is exposed
to widespread claims for probiotics with a variety of
products in shops, without clear guidance as to which
might be useful. Clear, evidence-based guidance is there-
fore needed regarding the effectiveness of different
probiotics and their clinical use.
Clinical guidelines usually focus on speciﬁc disease
entities, but primary care physicians and gastroenterolo-
gists working in the ﬁeld of FGID generally have to deal
with overlapping symptom complexes.20 Consequently,
the aim of this study was to provide practical advice to
clinicians regarding the use of probiotics in the treat-
ment of lower GI symptoms in adults in clinical practice.
This advice was based on an extensive review of the lit-
erature followed by a validated approach to developing
consensus that crosses international boundaries. The
ﬁndings were translated into a reference tool identifying
available probiotics with evidence for/against a beneﬁcial
effect for different GI symptoms/problems, to help
clinicians make appropriate, evidence-based treatment
decisions.
METHODS
Systematic literature searches
Systematic literature searches were performed (based on
AGREE II criteria21) to answer the following question: in
high-quality clinical studies performed in adults, what
effects do probiotics have on lower GI symptoms/
problems that are typically managed in primary care?
PubMed and Embase (which together provide extensive
coverage of the biomedical literature) were searched to
identify all studies that assessed the effect of probiotics
on lower GI symptoms, using the search string shown in
Figure 1. The search results were combined and dupli-
cates were removed. An initial screen of article titles and
abstracts was then performed to identify clinical trials of
probiotics that studied lower GI symptoms in adults
(≥18 years old). Only studies of adults were included
because the intestinal microbiota differ between children
and adults.14 In addition, trials that evaluated only syn-
biotics were excluded. Studies of patients with IBS or
other FGID; diarrhoea as a side effect of antibiotic treat-
ment; lactose intolerance; or no speciﬁc GI diagnosis
were included. Studies of well-deﬁned disorders such as
inﬂammatory bowel disease and diverticular disease were
excluded. Studies of specialist populations (e.g. patients
with any type of cancer) were also excluded.
The output of the systematic literature searches was
discussed by the Consensus Group in a face-to-face
workshop. To ensure a high-quality evidence base, they
agreed to exclude the following: (i) studies without a pla-
cebo control group; (ii) crossover studies with a washout
period of less than 2 weeks; (iii) studies in which fewer
than 80% of participants were followed up unless the
study duration exceeded 4 weeks; (iv) studies that did
not perform a sample size calculation; (v) studies that
did not report symptom scores or clearly deﬁned
response rates for speciﬁc symptoms or symptom clus-
ters as prespeciﬁed primary or secondary end points.
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Prespeciﬁed primary/secondary end points were to be
listed as such in the Methods section or in the study
objectives at the end of the Introduction section of the
article under consideration.
Data for the following lower GI symptoms/problems
were extracted from the included articles: IBS; abdominal
pain; bloating/distension; ﬂatus; constipation; bowel habit
(e.g. frequency and/or consistency of bowel movements);
diarrhoea (as part of IBS or associated with use of anti-
biotics including Helicobacter pylori eradication therapy).
Health-related quality of life data were also extracted. As
it was evident from previous publications that different
probiotic strains will have different effects,10 the identi-
ties of the probiotic strains used in each study were
recorded. Results of adverse event monitoring were also
recorded if available.
Consensus development
A modiﬁed Delphi process was used to develop consen-
sus statements. The Delphi process is an increasingly
widely used technique for reaching expert consensus.22–24
It uses a process of anonymous and iterative feedback and
voting to achieve consensus among a panel of indepen-
dent experts by means of stepwise reﬁnement of
responses.
The Consensus Group consisted of primary care phy-
sicians with an interest in gastroenterology drawn from
the European Society for Primary Care Gastroenterology
(ESPCG), with the addition of one primary care physi-
cian from Belgium, two members from secondary care
and a microbiologist. The Group was led by a nonvoting
Chair (APSH, ESPCG Research Ofﬁcer) who, in com-
mon with other members of the Consensus Group, has
Search string:
(yogurt OR yoghurt OR probiotic* OR "lactic acid bacteria" OR "Streptococcus thermophilus" OR “S. thermophilus” OR
"fermented milk" OR Bifidobacter* OR Lactobacill* OR Lactococc* OR "Saccharomyces” OR “Bacillus mesentericus” OR “B.
mesentericus” OR “Enterococcus faecalis” OR “E. faecalis” OR “Enterococcus faecium” OR “E. faecium” OR “ Bacillus clausii” OR
“B. clausii” OR “Clostridium butyricum” OR “C. butyricum” OR “E. coli Nissle” OR “Escherichia coli Nissle” OR VSL#3) AND (IBS OR
“irritable bowel syndrome” OR “abdominal distension” OR “gas evacuation” OR “visceral hypersensitivity” OR bloating OR
flatulence OR flatus OR “abdominal pain” OR “digestive symptom” OR “stool consistency” OR “stool frequency” OR “stool quantity”
OR “urgency” OR “faecal incontinence” OR “fecal incontinence” OR defecation OR “bowel movement” OR “bowel habit” OR
transit OR constipation OR diarrhea OR diarrhoea)
PubMed:
2269 hits 806 hits
Duplicates removed and
clinical trials of probiotics
describing lower Gl symptoms
in adults identified
287 clinical trials
37 papers for consideration
Embase:
Excluded
Studies lacking placebo control
Studies of synbiotics and sterile preparations
Studies of GI disorders typically managed in secondary care
Studies of specialist patient groups (e.g. patients with cancer)
Crossover studies with washout period <2 weeks
Studies lasting <4 weeks with <80% follow-up
Studies without a sample size calculation
Studies that did not report symptom scores or clearly defined response rates for
specific symptoms or symptom clusters as pre-specified primary or secondary
endpoints
•
•
•
•
•
•
•
•
Figure 1 | Flow diagram of literature searches. The initial PubMed and Embase searches were performed on 31 January
2012, and were limited to English language publications. GI, gastrointestinal.
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experience of systematic reviews and guideline develop-
ment. Statements were developed (based on evidence
and clinical experience) by the Chair in collaboration
with a Steering Committee (BP, NdW and PW).
Development and grading of statements
Statements were prepared for each of the categories out-
lined above. The level of supporting evidence and
strength of each statement were rated by the Chair and
Steering Committee using the Grades of Recommenda-
tion Assessment, Development and Evaluation (GRADE)
system25 as follows: high – further research is unlikely to
change our conﬁdence in the estimate of effect; moderate
– further research is likely to have an important impact
on our conﬁdence in the estimate of effect and may
change the estimate; low – further research is very likely
to have an important impact on our conﬁdence in the
estimate of effect and is likely to change the estimate;
and very low – any estimate of effect is very uncertain.
Reﬁnement of statements
The statements were worded to reﬂect the grade of avail-
able evidence. For example, the phrase ‘probiotics may
help to…’ was used to distinguish statements with a low
grade of evidence from those with a moderate or high
grade of evidence (‘probiotics help to…’). The propor-
tion of patients with IBS who responded to treatment
did not exceed 80% in the included studies (despite
‘responders’ being deﬁned very broadly as patients show-
ing any improvement from baseline in some studies).
Therefore, statements relating to potential beneﬁts in IBS
used the phrase ‘in some patients with IBS’ rather than
‘in patients with IBS’. Two rounds of anonymous voting
on the statements were performed. Votes were cast using
an online platform (INSINC Consulting, Guelph, ON,
Canada and ECD Solutions, Atlanta, GA, USA), with
each round being analysed by the nonvoting Chair
(APSH). For each statement, voters indicated their level
of agreement on a scale from 1 to 6 (1: strongly disagree;
2: disagree with major reservation; 3: disagree with
minor reservation; 4: agree with major reservation; 5:
agree with minor reservation; and 6: strongly agree).
Consensus was deﬁned a priori as agreement by at least
67% of respondents.
RESULTS
In total, 37 publications were identiﬁed and used to
develop statements. Table 1 provides a summary of the
symptoms and indications examined in the 37 studies,
all of which had a placebo control group or placebo-con-
trolled period. Collectively, the 37 studies investigated a
total of 32 different probiotics at doses of 1 9 106–
4.5 9 1011 colony forming units (CFU) administered
once, twice or three times daily. They predominantly
contained bacteria (mostly lactobacilli and/or biﬁdobacte-
ria); a few contained Saccharomyces. Of note, the term
‘probiotics’ has been used throughout this section to
refer to products that contain probiotics, regardless of
whether the product contains a single strain or multiple
strains.
Treatment adherence was addressed in 29 of the
included studies. In 27 of the included studies, adherence
to treatment was assessed by counting empty containers/
unused test substance returned at the end of the study
and/or by participant self-reporting (in treatment diaries
or during investigator visits). Faecal recovery of probiotic
Table 1 | Indications and symptoms examined in included studies
Number of studies
Indication
Symptom IBS
Functional
GI disorders
Antibiotic
treatment
Helicobacter
pylori
eradication
Lactose
intolerance
Healthy/minor
GI symptoms Total
IBS (global symptoms) 16 0 0 0 0 0 16
Abdominal pain 18 2 0 0 1 2 23
Bloating/distension 15 1 0 0 1 2 19
Flatus 10 2 0 0 1 2 15
Diarrhoea (treatment) 3 2 0 0 1 1 7
Diarrhoea (prevention) 0 0 6 4 0 0 10
Constipation 2 2 0 0 0 0 4
Bowel habit 17 1 0 0 0 3 21
Health-related quality of life 12 1 0 0 0 2 15
Total 19 2 6 4 1 5 37
GI, gastrointestinal; IBS, irritable bowel syndrome.
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strains was used as a measure of adherence in three of
the studies. Where adherence data were reported (21
studies), the level of adherence was generally high. In the
active treatment groups, the proportion of participants
who were adherent to treatment was >75–100%. In the
faecal recovery analyses, 79–92% of participants in the
active treatment groups tested positive for the speciﬁc
probiotic strain(s).
The majority of the studies focused on IBS (based on
Rome I, II or III criteria or physician diagnosis; 19 stud-
ies) or antibiotic-associated diarrhoea (AAD; 10 studies,
of which four examined H. pylori eradication therapy).
The studies in IBS tended to include all IBS subtypes,
with only two studies focusing on constipation-predomi-
nant IBS (IBS-C), and three studies focusing on diar-
rhoea-predominant IBS (IBS-D). The IBS studies
employed different deﬁnitions of treatment response and
reported a correspondingly wide range of ‘responder’
rates (18–80% and 5–50% in groups receiving speciﬁc
probiotics and placebo respectively). Table 2 provides an
overview of the 37 studies, including the indication stud-
ied, the probiotic treatment regimens used, study design
and the number of patients analysed.
Sixteen statements were developed, covering nine
symptoms or problems plus general considerations relat-
ing to probiotic use. Of the 16 statements, 11 achieved
consensus in the ﬁrst round of voting and 15 achieved
consensus in the second round (see Figure 2). Table 3
summarises the studies and speciﬁc probiotics with sup-
portive or nonsupportive evidence for each consensus
statement, together with an indication of whether the
result was a primary or secondary end point, or part of
a subanalysis. Table S1 shows probiotic availability in
Europe, the USA and China.
For each consensus statement, the result of the second
(ﬁnal) vote and the grade of supporting evidence are
given, followed by a discussion of the evidence. In some
cases, the consensus statement is indication-speciﬁc;
however, studies in other indications that provide rele-
vant data are also described for completeness. In the fol-
lowing discussion, ‘signiﬁcant’ refers to a statistically
signiﬁcant result (P < 0.05). Sometimes, a particular pro-
biotic yielded conﬂicting results for a symptom/problem
when it was investigated in different studies (see
Table 3).
Irritable bowel syndrome (global symptom
assessment)
Statement 1: speciﬁc probiotics help relieve overall
symptom burden in some patients with IBS. Agreement:
100% (6, 40%; 5, 50%; 4, 10%; grade of evidence for
effect: high).
Supportive evidence: Eleven studies of 10 different pro-
biotics evaluated overall symptoms in 1313 patients with
IBS. Of these studies, nine evaluated overall IBS symp-
toms as a primary end point, with ﬁve reporting a signif-
icant beneﬁcial effect of ﬁve different probiotic
treatments compared with placebo27, 28, 34, 56, 58 and
three reporting no signiﬁcant differences between two
speciﬁc probiotic treatments and placebo.26, 31, 32 One of
the nine studies reported a signiﬁcant improvement vs.
placebo in a subanalysis of patients with a Bristol stool
scale score of 3 or more at baseline, but no signiﬁcant
effect was seen in the overall study population.57 Two
studies of two different probiotics evaluated overall IBS
symptoms as a secondary end point only, with one
reporting a negative effect of the speciﬁc probiotic treat-
ment compared with placebo,59 and one dose-ranging
study33 reporting a beneﬁcial effect of the speciﬁc
probiotic treatment at the 1 9 108 CFU dose, but not at
the lower and higher doses tested (1 9 106 and
1 9 1010 CFU).
Statement 2: speciﬁc probiotics may help relieve overall
symptom burden in some patients with IBS-C. Agree-
ment: 80% (6, 10%; 5, 30%; 4, 40%; 3, 10%; 2, 10%;
grade of evidence for effect: low).
Supportive evidence: Three studies of two different
probiotics evaluated overall IBS symptoms as a second-
ary end point in 376 patients with IBS-C. One study
reported a beneﬁcial effect of the speciﬁc probiotic treat-
ment vs. placebo,35 and another study of the same pro-
biotic reported a signiﬁcant improvement from baseline
in the probiotic group, but not in the placebo group, in
a subanalysis of patients with fewer than three bowel
movements/week.36 One study of a different probiotic
reported no signiﬁcant improvement in symptoms vs.
placebo.33
Statement 3: speciﬁc probiotics help relieve overall
symptom burden in some patients with IBS-D. Agree-
ment: 100% (6, 10%; 5, 70%; 4, 20%; grade of evidence
for effect: moderate).
Supportive evidence: Four studies of four different pro-
biotics evaluated overall IBS symptoms in 305 patients
with IBS-D. Two studies evaluated overall IBS symptoms
as a primary end point, with one reporting a signiﬁcant
beneﬁcial effect of the speciﬁc probiotic treatment com-
pared with placebo,37 and one reporting no signiﬁcant
difference.38 Two studies evaluated overall IBS symptoms
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Table 2 | Overview of probiotic treatment regimens and results in included studies
Diagnosis
Patients
analysed
(n)
Study
design
Probiotic strain(s)* (brand name)
Formulation and regimen Primary end point Results for primary end point P value Reference
Marketed products
IBS (Rome II) 100 DBRCT Biﬁdobacterium longum subsp.
longum LA 101, Lactobacillus
acidophilus LA 102, L. delbrueckii
subsp. lactis LA 103, Streptococcus
salivarius subsp. thermophilus LA
104 (Lactibiane)
Sachets, 1 9 1010 CFU o.i.d.
for 4 weeks
Satisfactory relief of overall
IBS symptoms, and
abdominal pain/discomfort
score
Proportion with satisfactory
relief: speciﬁc probiotic,
42.6%; placebo, 42.3%.
Reduction in abdominal
pain score from ﬁrst to
fourth week of treatment:
speciﬁc probiotic, 41.9%;
placebo, 24.2%
> 0.05
0.048
Drouault-
Holowacz
et al.26
IBS, including
abdominal
pain (diagnosed
by a primary
care physician)
298 DBRCT Escherichia coli DSM17252
(Symbioﬂor-2)
Oral liquid, 1.5–4.5 9 107
CFU/mL for 8 weeks
(0.75 mL t.i.d. for week 1;
1.5 mL t.i.d. for weeks 2–8)
Abdominal pain and overall
IBS symptom scores
(treatment response:
absence of symptoms
at ≥1 visit during treatment)
Abdominal pain response rate:
speciﬁc probiotic, 18.9%;
placebo, 6.7%
Overall GI symptom
response rate:
speciﬁc probiotic, 18.2%;
placebo, 4.7%
0.0016
0.0004
Enck
et al.27
IBS (Rome II) 86 DBRCT L. rhamnosus GG, L. rhamnosus
Lc705, Propionibacterium
freudenreichii subsp. shermanii JS,
B. animalis subsp. lactis Bb12
(Geﬁlus MAX)
Milk-based drink, 1.2 dL
(1 9 107 CFU/mL of each
strain) o.i.d. for 5 months
Change in composite IBS
symptom score
(abdominal pain,
distension, ﬂatulence and
rumbling)
Decrease from baseline:
speciﬁc probiotic, 37%;
placebo, 9%
0.0083 Kajander
et al.28
IBS (Rome II)
with
abdominal
bloating
48 DBRCT B. longum subsp. longum, B. infantis
subsp. infantis, B. breve,
L. acidophilus, L. paracasei subsp.
paracasei, L. delbrueckii subsp.
bulgaricus, L. plantarum,
Streptococcus salivarius subsp.
thermophilus (VSL#3)
One sachet (450 billion lyophilised
bacteria) b.i.d. for 4–8 weeks
Bloating severity score Posttreatment score: speciﬁc
probiotic, 31.3; placebo, 38.5
0.11 Kim et al.29
IBS (Rome
criteria)
12 DBRCT,
crossover
L. plantarum 299v (ProViva)
Fermented oatmeal gruel,
6.25 9 109 CFU o.i.d. (125 mL) for
4 weeks
Gas production Gas production in 24 h: speciﬁc
probiotic, 249 mL; placebo,
245 mL
>0.05 Sen et al.30
IBS (Rome II) 74 DBRCT L. paracasei subsp. paracasei F19,
L. acidophilus La5, B. animalis subsp.
lactis Bb12 (Cultura)
Fermented milk, 5 9 107 CFU/mL,
200 mL b.i.d. for 8 weeks
Proportion of patients
reporting adequate relief of
their IBS symptoms at
least 50% of the weeks
during the treatment
period (‘responders’)
Proportion of responders:
speciﬁc probiotic, 38%;
placebo, 27%
0.3 Simren
et al.31
IBS (Rome II) 52 DBRCT L. paracasei subsp. paracasei F19,
L. acidophilus La5, B. animalis subsp.
lactis Bb 12 (Cultura)
Fermented milk, 250 mL
b.i.d. (7.5 9 1010 CFU/day)
for 8 weeks
Proportion reporting
adequate symptom relief,
and total IBS-SSI score
No signiﬁcant differences
between speciﬁc probiotic
and placebo
>0.05 Sondergaard
et al.32
IBS (Rome II;
females)
362 DBRCT B. longum subsp. infantis 35624
(Bifantis/Align)
Capsules, three dose groups:
1 9 106, 1 9 108 or
1 9 1010 CFU o.i.d. for 4 weeks
Abdominal pain/discomfort
score
Change from baseline: 0.89
in the group receiving speciﬁc
probiotic 1 9 108 CFU o.i.d.
compared to 0.58 in the
placebo group
0.023 Whorwell
et al.33
IBS (Rome II) 52 DBRCT L. acidophilus (CUL60 and CUL21),
B. animalis subsp. lactis CUL34,
B. biﬁdum CUL20 (LAB4)
Capsules, 2.5 9 1010 CFU o.i.d.
for 8 weeks
IBS-SSI score Difference (speciﬁc probiotic vs.
placebo): 6 weeks: –47.82
8 weeks: –52.73
10 weeks: no signiﬁcant
difference
0.0347
0.0217
>0.05
Williams
et al.34
IBS-C
(Rome III)
34 DBRCT B. animalis subsp. lactis DN-173 010
(Activia)
Fermented milk, 125 g
(1.25 9 1010 CFU) b.i.d. for
4 weeks
Abdominal distension
(measured by abdominal
inductance
plethysmography)
Median percentage change in
maximal distension (speciﬁc
probiotic vs. placebo): 39%
Mean abdominal distension
(speciﬁc probiotic vs. placebo):
1.52 cm
0.02
0.096
Agrawal
et al.35
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Table 2 | (Continued)
Diagnosis
Patients
analysed
(n)
Study
design
Probiotic strain(s)* (brand name)
Formulation and regimen Primary end point Results for primary end point P value Reference
IBS-C
(Rome II)
267 DBRCT B. animalis subsp. lactis DN-173 010
(Activia)
Fermented milk, 125 g
(1.25 9 1010 CFU) b.i.d. for
6 weeks
‘Discomfort’ dimension of
the validated FDDQOL
questionnaire (response:
improvement of ≥ 10% vs.
baseline)
Responder rate (week 3):
speciﬁc probiotic, 65.2%;
placebo, 47.7%
Responder rate (week 6):
speciﬁc probiotic, 63.0%;
placebo, 56.8%)
Change in score from baseline:
no signiﬁcant difference
between groups
0.003
>0.05
>0.05
Guyonnet
et al.36
IBS-D
(Rome III)
50 DBRCT L. acidophilus LH5, L. plantarum LP1,
L. rhamnosus LR3, B. breve BR2,
B. animalis subsp. lactis BL2,
B. longum subsp. longum BG3,
Streptococcus salivarius subsp.
thermophilus ST3 (bacterial
component of Duolac7)
One capsule b.i.d.
(1 9 1010 cells/day)
for 8 weeks
Adequate relief of IBS
symptoms for ≥50% of
weeks during treatment
and 2-week follow-up
Proportion with adequate
symptom relief: speciﬁc
probiotic, 48%; placebo, 12%
0.01 Ki Cha
et al.37
IBS-D
(Rome II)
25 DBRCT B. longum, B. longum subsp. infantis,
B. breve, L. acidophilus, L. paracasei
subsp. paracasei, L. delbrueckii
subsp. bulgaricus, L. plantarum,
Streptococcus salivarius subsp.
thermophilus (VSL#3)
One sachet (225 billion
lyophilised bacteria) b.i.d.
for 8 weeks (total daily dose
450 billion bacteria)
Transit time and global
satisfaction (treatment
response: satisfactory
relief of overall IBS
symptoms on ≥4 of 8
weekly assessments)
GI transit: no difference
between the two treatment
groups.
Proportion of responders:
speciﬁc probiotic,
33%; placebo, 38%
0.41
–0.99
1.00
Kim
et al.38
IBS-D
(Rome II)
29 SBRCT Streptococcus salivarius subsp.
thermophilus (1 9 108 CFU/mL),
L. delbrueckii subsp. bulgaricus
(1 9 107 CFU/mL), L. acidophilus
(1 9 107 CFU/mL), B. longum
subsp. longum (1 9 107 CFU/mL)
(AB100 Jianneng)
Fermented milk, 200 g b.i.d.
for 4 weeks (each mL contained
at least 1.3 9 108 CFU total)
Improvement in proportion
with abnormal intestinal
permeability
N/A – primary end point data
were not GI symptoms/HRQoL
measures (IBS symptoms were
assessed as secondary end
points)
– Zeng
et al.39
AAD 89 DBRCT L. acidophilus CL1285, L. paracasei
subsp. paracasei LBC80R (Bio-K+
CL1285)
Fermented milk, half container
(49 g) o.i.d. for 2 days,
then full container (98 g;
50 9 109 CFU) o.i.d., starting
within 48 h of initiating antibiotic
treatment and continuing for
duration of antibiotic treatment
AAD (≥3 liquid stools in a
24-h period)
Incidence of AAD: speciﬁc
probiotic, 15.9%; placebo,
35.6%; OR, 0.343
0.05 Beausoleil
et al.40
AAD 255 DBRCT L. acidophilus CLl285, L. paracasei
subsp. paracasei LBC80R (Bio-K+
CL1285)
Capsules, two dose groups:
One or two probiotic capsules
(50 or 100 billion CFU)/day,
initiated within 36 h of starting
antibiotic treatment and
continued for 5 days after
completing antibiotic treatment
(duration of antibiotic treatment
was 3–14 days)
AAD (≥3 liquid stools in a
24-h period)
Incidence of AAD: speciﬁc
probiotic (two capsules),
15.5%; speciﬁc probiotic (one
capsule); 28.2%; placebo,
44.1%
Duration of AAD:
speciﬁc probiotic (two
capsules), 2.8 days; speciﬁc
probiotic (one capsule);
4.1 days; placebo, 6.4 days
≤0.02
<0.001
Gao et al.41
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Table 2 | (Continued)
Diagnosis
Patients
analysed
(n)
Study
design
Probiotic strain(s)* (brand name)
Formulation and regimen Primary end point Results for primary end point P value Reference
AAD 437 DBRCT L. acidophilus CL1285, L. paracasei
subsp. paracasei LBC80R (Bio-K+
CL1285)
Fermented milk, half container
(49 g) o.i.d. for 2 days,
then full container (98 g;
50 9 109 CFU) o.i.d. for 29–
40 days (started within 24 h after
the ﬁrst dose of antibiotic, and
continued until 5 days after the
last dose of antibiotic)
AAD (≥1 episodes of
unformed or liquid stool in
a 24-h period) severity
and incidence
Mean number of days with
AAD: speciﬁc probiotic,
0.67 days; placebo, 1.19 days
Proportion of patients
with AAD: speciﬁc probiotic,
21.8%; placebo, 29.4% (note
study was underpowered).
OR of AAD (multivariate
logistic regression,
speciﬁc probiotic
vs. placebo): 0.627
0.040
0.067
0.037
Sampalis
et al.42
AAD 113 DBRCT L. paracasei subsp. paracasei DN-114
001 (L. paracasei subsp. paracasei
immunitass) (Actimel)
Yoghurt drink, 100 g (97 mL;
1 9 108 CFU/mL) b.i.d. started
within 48 h of starting antibiotic
treatment and continued for
1 week after stopping antibiotic
treatment (publication does not
state duration of antibiotics).
Follow-up was 4 weeks later
AAD (>2 liquid stools a day
for ≥3 days in quantities in
excess of normal for the
patient)
Incidence of AAD: speciﬁc
probiotic, 12%; placebo, 34%
OR of diarrhoea (adjusted
logistic regression, speciﬁc
probiotic vs. placebo): 0.25
0.007 Hickson
et al.43
AAD,
Clostridium
difﬁcile-
associated
diarrhoea
138 DBRCT L. acidophilus (CUL60 and CUL21),
B. animalis subsp. lactis CUL34,
B. biﬁdum CUL20 (LAB4; strains
not given in publication;
information obtained from
company website)
Capsules, 2 9 1010 CFU
o.i.d. started within
36 h of antibiotic prescription
(duration 20 days)
C. difﬁcile-associated
diarrhoea
N/A – C. difﬁcile-associated
diarrhoea was not covered in
this consensus (AAD was
assessed as a secondary end
point)
– Plummer
et al.44
AAD 214 DBRCT L. rhamnosus R0011, L. acidophilus
R0052 (Lacidoﬁl cap)
One capsule (2 9 109 CFU) b.i.d.
starting within 48 h of initiating
antibiotic treatment (duration
2 weeks)
AAD (loose or watery
stools >39 per day for
≥2 days within 14 days of
enrolment)
Incidence of AAD: speciﬁc
probiotic, 3.9%; placebo, 7.2%
(note study was
underpowered)
0.44 Song
et al.45
H. pylori
therapy-
associated
side effects
124 DBRCT Saccharomyces boulardii (Reﬂor)
500 mg (two sachets) b.i.d. for
2 weeks during 2-week H. pylori
eradication therapy. Patients were
followed up for a further 2 weeks
H. pylori eradication
therapy-associated side
effects
Diarrhoea occurred in 14.5% of
the speciﬁc probiotic group
and 30.6% of the placebo
group
<0.05 Cindoruk
et al.46
H. pylori
therapy-
associated
side effects
64 TBRCT (1) L. rhamnosus GG (Giﬂorex)
Saccharomyces boulardii† (Codex)
(2) One sachet b.i.d. for 2 weeks
(during and for 1 week after
1-week H. pylori eradication
therapy). Each sachet contained
6 9 109 CFU (1) or 5 9 109 CFU (2)
H. pylori eradication
therapy-associated side
effects
Diarrhoea occurred in 5% of
each speciﬁc probiotic group,
compared to 30% of the
placebo group
0.018 Cremonini
et al.47
H. pylori
therapy-
associated
side effects
88 DBRCT L. acidophilus LA-5, B. animalis
subsp. lactis Bb12, Streptococcus
salivarius subsp. thermophilus (ABT-
21 culture)
Fermented milk, 125 g
b.i.d. (≥1 9 106 CFU/g of each
strain) for 5 weeks (eradication
triple therapy during ﬁfth week of
study intervention)
H. pylori eradication
therapy-associated
diarrhoea episodes (≥3
watery stools per day, with
≥1 day in the eradication
week)
Number of diarrhoea episodes:
active speciﬁc probiotic, 4;
pasteurised speciﬁc probiotic,
2; acidiﬁed milk, 3
Number of days with
watery stools: active
speciﬁc probiotic, 4;
pasteurised speciﬁc probiotic,
10; acidiﬁed milk, 10
Mean duration of diarrhoea
episodes: active speciﬁc
probiotic, 1.0 day; pasteurised
speciﬁc probiotic, 5.0 days;
acidiﬁed milk, 4.7 days
>0.05
<0.05
<0.05
de Vrese
et al.48
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Table 2 | (Continued)
Diagnosis
Patients
analysed
(n)
Study
design
Probiotic strain(s)* (brand name)
Formulation and regimen Primary end point Results for primary end point P value Reference
H. pylori
therapy-
associated
side effects
106 DBRCT Bacillus clausii strains O/C, N/R, T
and SIN (Enterogermina)
One vial (each vial contains
2 9 109 spores of Bacillus
clausii) t.i.d., taken during 1 week
of H. pylori eradication therapy
and continued for 1 further week
H. pylori eradication
therapy-associated side
effects
Incidence of diarrhoea after
1 week: speciﬁc probiotic,
9.3%; placebo, 30.8%; RR:
0.30. Mean intensity and
frequency of diarrhoea
episodes were also reduced
<0.01 Nista
et al.49
Functional GI
symptoms
87 TBRCT B. animalis subsp. lactis HN019
(HOWARU Biﬁdo/DR10)
Capsules, two dose groups:
1.8 billion or 17.2 billion CFU/day
for 2 weeks
Whole-gut transit time Change from baseline: speciﬁc
probiotic groups, 25% and
33%; placebo group, +17%
<0.001 Waller
et al.50
Women with
mild digestive
symptoms
197 DBRCT B. animalis subsp. lactis DN-173 010
(Activia)
Fermented milk, 125 g
(1.25 9 1010 CFU) b.i.d. for
4 weeks
GI well-being Proportion reporting improved
GI well-being at weeks 1–4:
speciﬁc probiotic, 37–41%;
placebo, 22–34%; OR, 1.7
0.006 Guyonnet
et al.51
Healthy,
postprandial
intestinal
gas-related
symptoms
61 DBRCT Bacillus coagulans GBI-30, 6086
(Digestive Advantage Gas Defense
Formula)
One capsule (2 9 109 CFU)
o.i.d. for 4 weeks
GSRS abdominal pain,
distension and ﬂatus
subscores, and SODA
bloating and gas subscores
Difference between speciﬁc
probiotic and placebo groups
at 4 weeks:
Abdominal pain
(GSRS), 0.627
Abdominal distension
(GSRS), 0.572
Flatus (GSRS), 0.511
Bloating (SODA): 0.229
Gas (SODA):  0.348
0.046
0.061
0.154
0.294
0.118
Kalman
et al.52
Lactose-
intolerant
individuals
60 RCT L. reuteri DSM17938 (Reuterin)
Two pills b.i.d. (4 9 108
CFU/day) for 10 days preceding
lactose breath test
Lactose breath test
normalisation rate
N/A – primary end point data
were not GI symptoms/
HRQoL measures (bloating,
abdominal pain, ﬂatus and
diarrhoea were assessed
as secondary end points)
– Ojetti
et al.53
Elderly
nursing
home
residents
179 DBRCT (1) B. longum subsp. longum 46 and
2C, (2) B. animalis subsp. lactis
Bb12 (Yosa)
Fermented oat drinks,
1 9 109 CFU/day (200 mL) for
7 months
Proportion of participants
with bowel functioning
on >30% of days
Bowel functioning on ≥30% of
days: placebo, 49%
speciﬁc probiotic 1, 70%
speciﬁc probiotic 2, 59%
Normal bowel functioning
(solid or normal consistency
of stools) on ≥30 days:
placebo, 14%
speciﬁc probiotic 1, 37%
speciﬁc probiotic 2, 30%
0.044
0.253
0.020
0.036
Pitkala
et al.54
Healthy
individuals
(competitive
cyclists)
88 DBRCT L. fermentum VRI-003 (PCC)
(ProBioPCC)
One capsule (≥1 9 109 CFU) o.i.d.
for 11 weeks (mean)
Self-reported upper
respiratory tract and GI
symptoms
GI symptoms
Ratio (99% CI) of number
of episodes (speciﬁc
probiotic/placebo):
men, 2.06 (0.51–11);
women, 3.02 (0.76–17)
Ratio (99% CI) of duration
of episodes (speciﬁc
probiotic/placebo):
men, 2.57 (0.53–17);
women, 1.85 (0.35–27)
Difference (99% CI) in severity
(speciﬁc probiotic  placebo):
men, 0.47 (1.21 to 0.28);
women, 0.31 (1.39 to 0.79)
Upper respiratory tract
symptoms: no clear
difference between groups
– West
et al.55
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Table 2 | (Continued)
Diagnosis
Patients
analysed
(n)
Study
design
Probiotic strain(s)* (brand name)
Formulation and regimen Primary end point Results for primary end point P value Reference
Investigative strains
IBS (mild-to-
moderate;
Rome III)
122 DBRCT B. biﬁdum MIMBb75
One capsule
(1 9 109 CFU) o.i.d. for 4 weeks
Global IBS symptoms
(7-point Likert scale)
Improvement from baseline:
speciﬁc probiotic, 0.88;
placebo, 0.16
<0.0001 Guglielmetti
et al.56
IBS (Rome III) 70 DBRCT B. biﬁdum BGN4, B. animalis subsp.
lactis AD011, L. acidophilus AD031,
L. paracasei subsp. paracasei
IBS041
One sachet b.i.d. (10 billion
bacteria of each strain/day) for
8 weeks
Abdominal pain, ﬂatus,
defecation discomfort
individual and sum scores
Abdominal pain (vs. baseline):
Week 4: speciﬁc probiotic,
23.9; placebo, 10.9
Week 8: speciﬁc probiotic,
31.9; placebo, 17.7
Flatus (vs. baseline):
Week 4: speciﬁc probiotic,
18.5; placebo, 18.4
Week 8: speciﬁc probiotic,
27.0; placebo, 21.3
Defecation discomfort
(vs. baseline):
Week 4: speciﬁc probiotic,
29.2; placebo, 13.5
Week 8: speciﬁc probiotic,
30.5; placebo, 18.4
Sum score (vs. baseline):
Week 4: speciﬁc probiotic,
71.7; placebo, 42.8
Week 8: speciﬁc probiotic,
89.5; placebo, 57.5
0.061
0.045
0.982
0.437
0.043
0.122
0.115
0.064
Hong et al.57
IBS (Rome I) 81 DBRCT L. rhamnosus GG, L. rhamnosus
Lc705, Propionibacterium
freudenreichii subsp. shermanii JS,
B. breve Bb99
One capsule (8–9 9 109 CFU total;
equal amount of each strain)
o.i.d. for 6 months
Change in weekly sum score
of each of four symptoms
(abdominal pain, distension,
ﬂatus and borborygmi),
total symptom score and
bowel habit
Baseline-adjusted symptom
score, difference between
speciﬁc probiotic and placebo:
Abdominal pain: 1.5
Distension: 1.6
Flatus: 1.2
Borborygmi: 2.2
Total symptom score: 6.5
Weekly defecation
frequency: 1.3
0.110
0.083
0.232
0.008
0.037
0.102
Kajander
et al.58
IBS (Rome II) 16 DBRCT,
crossover
L. plantarum MF1298
One capsule (1 9 1010
CFU) o.i.d. for 3 weeks
Treatment preference 13 participants (81%) preferred
placebo to the speciﬁc
probiotic
0.012 Ligaarden
et al.59
IBS (Rome III) 40 SBRCT L. acidophilus-SDC 2012,
L. acidophilus-SDC 2013
2 9 109 CFU/mL in one
capsule taken b.i.d. for
4 weeks
Abdominal pain (responder
rate)
Proportion with improvement in
abdominal pain/discomfort:
speciﬁc probiotic, 80%;
placebo, 35%
0.011 Sinn et al.60
Functional GI
disorders
72 DBRCT (1) L. acidophilus, B. biﬁdum, Bacillus
subtilis, L. delbrueckii subsp.
bulgaricus, L. delbrueckii subsp. lactis
and Bacillus lichenformis, or (2)
L. acidophilus, B. biﬁdum,
L. delbrueckii subsp. bulgaricus,
L. delbrueckii subsp. lactis, L. brevis,
L. caucasicus (nomina rejicienda;
now L. delbrueckii subsp.
delbrueckii), L. fermentum,
L. leichmanii, L. paracasei subsp.
paracasei, L. plantarum, L. helveticus
and Saccharomyces boulardii
Caplets, each containing
5 9 107 bacteria, taken for
12 weeks (Week 1: one caplet od;
Week 2: one caplet t.i.d.;
Week 3: two caplets t.i.d.;
Week 4: three caplets t.i.d.;
Weeks 5–12: four caplets t.i.d.)
HRQoL (GIQLI) GIQLI total score and well-being
subscales (physical, social and
mental) showed no signiﬁcant
change from baseline at 4, 8
and 12 weeks
>0.05 Kim et al.61
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as a secondary end point only, and both reported a sig-
niﬁcant beneﬁcial effect of the speciﬁc probiotic treat-
ments33, 39; one of these was a post hoc analysis of the
most effective dose in a subset of patients with IBS-D.33
Abdominal pain
Statement 4: speciﬁc probiotics help reduce abdominal
pain in some patients with IBS. Agreement: 100% (6,
30%; 5, 50%; 4, 20%, grade of evidence for effect: high).
Supportive evidence: Eighteen studies of 15 different
probiotics evaluated abdominal pain in 1806 patients with
IBS. Of these studies, six (each examining a different pro-
biotic) evaluated abdominal pain as a primary end point,
with four showing a signiﬁcant beneﬁcial effect of speciﬁc
probiotic treatments compared with placebo,27, 33, 57, 60
one58 showing a trend towards a beneﬁcial effect in the
weekly symptom score for abdominal pain (in a secondary
analysis, abdominal pain was reduced in a signiﬁcantly
greater proportion of the probiotic group than the placebo
group) and one26 showing no signiﬁcant increase in the
proportion of patients reporting symptom relief, but a sig-
niﬁcantly greater decrease in the abdominal pain score in
the probiotic group than the placebo group. Twelve studies
evaluated abdominal pain as a secondary end point only.
Results from these studies were mixed: one reported a neg-
ative effect of the speciﬁc probiotic treatment,59 eight
(examining six different probiotics) reported no signiﬁcant
effect28, 29, 31, 32, 34, 36–38 and three reported a signiﬁcant
beneﬁcial effect of three different probiotics35, 39, 56 (one
of which35 also showed no signiﬁcant effect in another
study36).
Abdominal pain was examined in indications other
than IBS in ﬁve studies of six different probiotics. One
study examined abdominal pain as a primary end point
in individuals with symptoms related to postprandial
intestinal gas, and found a signiﬁcant improvement in
the probiotic group compared with the placebo group.52
Four studies examined abdominal pain as a secondary
end point only, with two reporting no signiﬁcant differ-
ence between three different probiotic treatments and
placebo,51, 61 and two (examining one probiotic in lac-
tose-intolerant individuals undergoing a hydrogen breath
test53 and a different probiotic in patients with func-
tional GI symptoms50) reporting signiﬁcantly improved
abdominal pain vs. baseline in the probiotic group, but
not in the placebo group.
Bloating/distension
Statement 5: speciﬁc probiotics help reduce bloating/
distension in some patients with IBS. Agreement: 70%
Number of
statements
Vote 1 (online) 7–19 Nov 2012
Vote 2 (online) 23 Nov–3 Dec 2012
16
16
11 (69%)
15 (94%)
15 statements with consensus
Number
(proportion)
of statements
with consensus
Figure 2 | Overview of Delphi consensus development
process and voting results.
Table 2 | (Continued)
Diagnosis
Patients
analysed
(n)
Study
design
Probiotic strain(s)* (brand name)
Formulation and regimen Primary end point Results for primary end point P value Reference
Healthy
young
adults
71 DBRCT B. animalis subsp. lactis Bb12, L.
paracasei subsp. paracasei
CRL-431
Capsules, four dose groups:
1 9 108, 109, 1010 or
1011 CFU o.i.d. for 3 weeks
Granulocyte activity N/A – primary end point data
were not GI symptoms/HRQoL
measures (bowel habit was
assessed as a secondary end
point)
– Larsen
et al.62
AAD, antibiotic-associated diarrhoea; b.i.d., twice daily; CFU, colony forming units; CI, conﬁdence interval; DBRCT double-blind randomised controlled trial; FDDQOL,
Functional Digestive Disorders Quality of Life; GI, gastrointestinal; GIQLI, Gastrointestinal Quality of Life Index; GSRS, Gastrointestinal Symptom Rating Scale; HRQoL,
health-related quality of life; IBS, irritable bowel syndrome; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS; o.i.d., once daily; OR, odds ratio;
N/A, not applicable; RCT, randomised controlled trial; RR, relative risk; SBRCT, single-blind randomised controlled trial; SODA, Severity of Dyspepsia Assessment; SSI,
Symptom Severity Index; TBRCT, triple-blind randomised controlled trial; t.i.d., three times daily.
* In some cases, the speciﬁc strain was not identiﬁed in the publication and could not be found elsewhere (e.g. it may be proprietary information).
† This study tested a third product (Ferzym) that was excluded from the current analysis because online information indicated that it was a synbiotic.
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Table 3 | Overview of statements, grading and probiotics (marketed products and investigative strains) with
supportive evidence. For many statements, the majority of the evidence came from populations with IBS, and the
statements were therefore focused on IBS. Probiotics studied in indications other than IBS are still included below, but
are placed in square brackets
Statement
Grade of
evidence
for effect
Level of
agreement
(%)
Probiotics for which studies show supportive
evidence of beneﬁt* – (bold font indicates
primary end point data)
Probiotics for which studies suggest a lack of
signiﬁcant beneﬁt* (bold font indicates primary
end point data)
1: Speciﬁc probiotics help relieve
overall symptom burden in some
patients with IBS
High 100 Biﬁdobacterium biﬁdum MIMBb75,56 B. longum
subsp. infantis 35624 (Bifantis/Align),33
Escherichia coli DSM17252 (Symbioﬂor-2),27
investigative combinations (BIFIDO,57 Valio
Bb9958), marketed combinations (Geﬁlus
MAX,28 LAB434)
Lactobacillus plantarum MF1298,59 marketed
combinations (Cultura,31, 32 Lactibiane26)
2: Speciﬁc probiotics may help
relieve overall symptom burden in
some patients with IBS-C
Low 80 B. animalis subsp. lactis DN-173 010
(Activia)35, 36
B. longum subsp. infantis 35624 (Bifantis/
Align)33
3: Speciﬁc probiotics help relieve
overall symptom burden in some
patients with IBS-D
Moderate 100 B. longum subsp. infantis 35624 (Bifantis/
Align),33 marketed combinations (AB100
Jianneng,39 Duolac737)
Marketed combination (VSL#3)38
4: Speciﬁc probiotics help reduce
abdominal pain in some patients
with IBS
High 100 [Bacillus coagulans GBI-30, 6086 (Digestive
Advantage Gas Defense Formula)52], B. animalis
subsp. lactis DN-173 010 (Activia),35 [B. animalis
subsp. lactis HN019 (HOWARU Biﬁdo/DR10)50],
B. biﬁdum MIMBb75,56 B. longum subsp. infantis
35624 (Bifantis/Align),33 Escherichia coli DSM17252
(Symbioﬂor-2),27 investigative combinations
(BIFIDO,57 SDC,60 Valio Bb9958), [L. reuteri
DSM17938 (Reuterin)53], marketed
combinations (AB100 Jianneng,39 Lactibiane26)
B. animalis subsp. lactis DN-173 010 (Activia),36
[B. animalis subsp. lactis DN-173 010
(Activia)51], investigative combinations
([GoL661], [GoL1261]), L. plantarum MF1298,59
marketed combinations (Cultura,31, 32
Duolac7,37 Geﬁlus MAX,28 LAB4,34
VSL#329, 38)
5: Speciﬁc probiotics help reduce
bloating/distension in some
patients with IBS
Moderate 70 B. animalis subsp. lactis DN-173 010 (Activia),35
B. animalis subsp. lactis DN-173 010 (Activia),36
B. biﬁdum MIMBb75,56 B. longum subsp. infantis
35624 (Bifantis/Align),33 Escherichia coli
DSM17252 (Symbioﬂor-2),27 [L. reuteri
DSM17938 (Reuterin)53], marketed
combinations (Geﬁlus MAX,28 LAB434)
[Bacillus coagulans GBI-30, 6086 (Digestive
Advantage Gas Defense Formula)52],
[B. animalis subsp. lactis DN-173 010 (Activia)51],
investigative combinations ([GoL661], [GoL1261],
Valio Bb9958), L. plantarum MF1298,59 marketed
combinations (AB100 Jianneng,39 Cultura,31, 32
Duolac7,37 VSL#3,29 VSL#338)
6: Probiotics tested to date do not
reduce ﬂatus in patients with IBS
Low 90 [B. animalis subsp. lactis DN-173 010
(Activia)51], [B. animalis subsp. lactis HN019
(HOWARU Biﬁdo/DR10)50], B. longum subsp.
infantis 35624 (Bifantis/Align),33 [L. reuteri
DSM17938 (Reuterin)53], marketed
combinations (AB100 Jianneng,39 VSL#329)
[Bacillus coagulans GBI-30, 6086 (Digestive
Advantage Gas Defense Formula)52], B. animalis
subsp. lactis DN-173 010 (Activia),35 investigative
combinations (BIFIDO,57 [GoL661], [GoL1261],
Valio Bb9958), L. plantarum 299v (ProViva),30
marketed combinations (Duolac7,37 Geﬁlus MAX,28
VSL#338)
7: Speciﬁc probiotics may help
reduce constipation in some
patients with IBS
Low 60 (no consensus) B. animalis subsp. lactis DN-173 010 (Activia),35
[B. animalis subsp. lactis HN019 (HOWARU
Biﬁdo/DR10)50]
B. biﬁdum MIMBb75,56 investigative
combinations ([GoL661], [GoL1261])
8: Speciﬁc probiotics help improve
frequency and/or consistency of
bowel movements in some
patients with IBS
Moderate 70 [B. animalis subsp. lactis Bb12 (Yosa)54],
B. animalis subsp. lactis DN-173 010
(Activia),35, 36 [B. animalis subsp. lactis
DN-173 010 (Activia)51], [B. animalis subsp.
lactis HN019 (HOWARU Biﬁdo/DR10)50],
B. biﬁdum MIMBb75,56 B. longum subsp. infantis
35624 (Bifantis/Align),33 Escherichia coli
DSM17252 (Symbioﬂor-2),27 investigative
combinations ([Bioferme54], [CH62], SDC,60
Valio Bb9958), marketed combinations
(Duolac7,37 LAB4,34 Lactibiane26)
Investigative combination (BIFIDO57),
L. plantarum MF129859, marketed combinations
(Cultura,31, 32 Geﬁlus MAX,28 VSL#3,38
VSL#329)
9: Probiotics tested to date do not
reduce diarrhoea in patients with
IBS
Very low 80 [L. reuteri DSM17938 (Reuterin)53] [B. animalis subsp. lactis Bb12 (Yosa)54],
[B. animalis subsp. lactis HN019 (HOWARU Biﬁdo/
DR10)50], investigative combinations ([Bioferme54],
[GoL661], [GoL1261]), L. plantarum MF1298,59
marketed combinations (Duolac7,37 Geﬁlus MAX28)
10: In patients receiving antibiotic
therapy, speciﬁc probiotics are
helpful as adjuvant therapy to
prevent, or reduce the duration of,
associated diarrhoea
High 100 L. paracasei subsp. paracasei DN-114 001
(Actimel),43 marketed combination (Bio-K+
CL1285)40–42
Marketed combinations (LAB4,44 Lacidoﬁl
cap – underpowered45)
11: In patients receiving
Helicobacter pylori eradication
therapy, speciﬁc probiotics are
helpful as adjuvant therapy to
prevent or reduce the duration/
intensity of associated diarrhoea
High 100 L. rhamnosus GG (Giﬂorex),47 marketed
combinations (ABT-21 culture,48
Enterogermina49), Saccharomyces boulardii
(Codex,47 Reﬂor46)
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Table 3 | (Continued)
Statement
Grade of
evidence
for effect
Level of
agreement
(%)
Probiotics for which studies show supportive
evidence of beneﬁt* – (bold font indicates
primary end point data)
Probiotics for which studies suggest a lack of
signiﬁcant beneﬁt* (bold font indicates primary
end point data)
12: With speciﬁc probiotics,
improvement of symptoms has
been shown to lead to
improvement in some aspects of
health-related quality of life
Moderate 80 B. animalis subsp. lactis DN-173 010 (Activia),51
B. animalis subsp. lactis DN-173 010 (Activia),36
B. biﬁdum MIMBb75,56 Escherichia coli
DSM17252 (Symbioﬂor-2),27 investigative
combination (GoL12),61 marketed combinations
(Duolac7,37 LAB4,34 Lactibiane26)
Bacillus coagulans GBI-30, 6086 (Digestive
Advantage Gas Defense Formula),52 B. longum
subsp. infantis 35624 (Bifantis/Align),33
investigative combinations (BIFIDO,57 GoL6,61
Valio Bb9958), marketed combinations
(Cultura,31, 32 Geﬁlus MAX28)
13: Probiotics have a favourable
safety proﬁle in patients with a
range of lower GI symptoms
typically managed in primary care
or general practice
High 100 B. animalis subsp. lactis DN-173 010 (Activia),36
B. animalis subsp. lactis HN019 (HOWARU Biﬁdo/
DR10),50 B. biﬁdum MIMBb75,56 B. longum subsp.
infantis 35624 (Bifantis/Align),33 investigative
combinations (BIFIDO,57 CH,62 GoL6,61 GoL12,61
SDC,60 Valio Bb9958), L. paracasei subsp. paracasei
DN-114 001 (Actimel),43 L. rhamnosus GG
(Giﬂorex),47 marketed combinations (AB100
Jianneng,39 ABT-21 culture,48 Bio-K+ CL1285,40–42
Cultura, Duolac7,37 Geﬁlus MAX,28 LAB4,34
Lacidoﬁl cap,45 VSL#329, 38), Saccharomyces
boulardii (Codex,47 Reﬂor46)
Escherichia coli DSM17252 (Symbioﬂor-2),27
L. fermentum VRI-003 PCC,55 L. plantarum
MF129859
14: Speciﬁc probiotics have a role
in the management of some IBS
symptoms and can also be used
as an adjunct to conventional
treatment
NA 90 – –
15: Probiotic strains should be
selected based on the patient’s
symptoms, the clinical indication
and the available evidence; no
probiotic alleviates the full range
of symptoms in IBS
NA 80 – –
16: When trying a probiotic therapy
for a chronic GI problem, the
product should be taken for
1 month; dose selection should be
based on available evidence and
manufacturers’ recommendations
NA 80 – –
IBS, irritable bowel syndrome; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS.
* For simplicity, single-strain probiotics are identiﬁed by the name of the strain (and the brand name where available), and multi-strain products are identiﬁed as ‘combination (X)’
and listed in full below.
Investigative combinations: Valio Bb99: Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii subsp. shermanii JS and Biﬁdobacterium breve Bb99 (Valio
Ltd, Helsinki, Finland).
BIFIDO: Biﬁdobacterium biﬁdum BGN4, B. animalis subsp. lactis AD011, Lactobacillus acidophilus AD031 and L. paracasei subsp. paracasei IBS041 (BIFIDO Co. Ltd, Hongchun, Korea).
Bioferme: Biﬁdobacterium longum subsp. longum 46 and B. longum subsp. longum 2C (Bioferme Ltd, Kaarina, Finland).
CH: Biﬁdobacterium animalis subsp. lactis Bb12 and Lactobacillus paracasei subsp. paracasei CRL-431 (Chr. Hansen A/S, Hoersholm, Denmark).
GoL6 contains nonspeciﬁed strains from the species: Lactobacillus acidophilus, Biﬁdobacterium biﬁdum, Bacillus subtilis, L. delbrueckii subsp. bulgaricus, L. delbrueckii subsp. lactis and
Bacillus lichenformis (Garden of Life, West Palm, FL, USA).
GoL12 contains nonspeciﬁed strains from the species: Lactobacillus acidophilus, Biﬁdobacterium biﬁdum, L. delbrueckii subsp. bulgaricus, L. delbrueckii subsp. lactis, L. brevis, L. caucasicus
(nomina rejicienda; now L. delbrueckii subsp. delbrueckii), L. fermentum, L. leichmanii, L. paracasei subsp. paracasei, L. plantarum, L. helveticus and Saccharomyces boulardii (Garden of Life,
West Palm, FL, USA).
SDC: Lactobacillus acidophilus-SDC 2012 and L. acidophilus-SDC 2013 (Seoul Dairy Cooperative, Seoul, Korea).
Marketed combinations: AB100 Jianneng: Streptococcus salivarius subsp. thermophilus, Lactobacillus delbrueckii subsp. bulgaricus, L. acidophilus and Biﬁdobacterium longum subsp. lon-
gum (Bright Dairy, Shanghai, China).
ABT-21 culture: Lactobacillus acidophilus LA-5, Biﬁdobacterium animalis subsp. lactis Bb12 and Streptococcus salivarius subsp. thermophilus (Christian Hansen, Nienburg, Germany).
Bio-K+ CL1285: Lactobacillus acidophilus CL1285 and L. paracasei subsp. paracasei LBC80R (Bio-K+ International Inc., Quebec, QC, Canada).
Cultura: Lactobacillus paracasei subsp. paracasei F19, L. acidophilus La5 and Biﬁdobacterium animalis subsp. lactis Bb12 (Arla Foods Innovation, Stockholm, Sweden).
Duolac7: Lactobacillus acidophilus LH5, L. plantarum LP1, L. rhamnosus LR3, Biﬁdobacterium breve BR2, B. animalis subsp. lactis BL2, B. longum subsp. longum BG3 and Streptococcus sali-
varius subsp. thermophilus ST3 (Cell Biotech, Co. Ltd, Seoul, Korea).
Enterogermina: Bacillus clausii strains O/C, N/R, T and SIN (Sanoﬁ Synthelabo OTC, Milan, Italy).
Geﬁlus MAX: Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii subsp. shermanii JS and Biﬁdobacterium animalis subsp. lactis Bb12 (Valio Ltd, Helsinki,
Finland).
LAB4: Lactobacillus acidophilus (CUL60 and CUL21), Biﬁdobacterium animalis subsp. lactis CUL34 and B. biﬁdum CUL20 (Cultech, Port Talbot, UK).
Lacidoﬁl cap: Lactobacillus rhamnosus R0011 and L. acidophilus R0052 (Lallemand Inc., Montreal, QC, Canada).
Lactibiane: Biﬁdobacterium longum subsp. longum LA 101, Lactobacillus acidophilus LA 102, L. delbrueckii subsp. lactis LA 103 and Streptococcus salivarius subsp. thermophilus LA 104
(PiLeJe, Paris, France).
VSL#3: Biﬁdobacterium longum subsp. longum, B. infantis subsp. infantis, B. breve, Lactobacillus acidophilus, L. paracasei subsp. paracasei, L. delbrueckii subsp. bulgaricus, L. plantarum and
Streptococcus salivarius subsp. thermophilus (VSL Pharmaceuticals Inc., Gaithersburg, MD, USA).
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(6, 10%; 5, 30%; 4, 30%; 3, 20%; 2, 10%; grade of evi-
dence for effect: moderate).
Supportive evidence: Fifteen studies of 12 different
probiotics evaluated treatment of bloating/distension in
1596 patients with IBS. Of these studies, three (examin-
ing three different probiotics) evaluated bloating/disten-
sion as a primary end point, with one reporting a
signiﬁcant, beneﬁcial effect of the speciﬁc probiotic
treatment vs. placebo,35 and two reporting no signiﬁ-
cant differences.29, 58 Twelve studies evaluated bloating/
distension as a secondary end point only, with six
reporting a signiﬁcant, beneﬁcial effect of six different
probiotic treatments27, 28, 33, 34, 36, 56 (one of which36
also showed a beneﬁcial effect as a primary end point
in another study35). In one study,36 the signiﬁcant effect
was seen at week 3, but not at week 6, and in
another,33 the signiﬁcant effect was seen at one speciﬁc
dose only. The remaining six studies reported no signif-
icant difference between ﬁve different probiotic treat-
ments and placebo31, 32, 37–39, 59 (one of these
probiotics38 also showed no signiﬁcant effect as a
primary end point29).
Four studies investigated the effect of ﬁve different
probiotics on distension/bloating in indications other
than IBS. One study evaluated symptoms related to post-
prandial intestinal gas as a primary end point in healthy
individuals and reported no signiﬁcant differences
between the probiotic and placebo groups.52 The remain-
ing three studies (of four different probiotics) evaluated
distension/bloating as a secondary end point, with single
studies reporting no signiﬁcant differences between the
probiotic and control groups in women with mild diges-
tive symptoms51 and patients with FGID.61 The third
study, in individuals with lactose intolerance undergoing
a hydrogen breath test, reported signiﬁcantly reduced
bloating in the group receiving the speciﬁc probiotic
treatment, but no signiﬁcant improvement in the placebo
group.53
Flatus
Statement 6: probiotics tested to date do not help
reduce ﬂatus in patients with IBS. Agreement: 90% (6,
20%; 5, 30%; 4, 40%; 2, 10%; grade of evidence for effect:
low).
Supportive evidence: Overall, 10 studies, using nine dif-
ferent probiotics, evaluated ﬂatus in 797 patients with
IBS. The statement on ﬂatus had to be formulated in the
negative as there was a low level of agreement when it
was formed in the positive. This was because the evi-
dence in IBS studies was weak: all three studies that
examined ﬂatus as a primary end point,30, 57, 58 and four
of seven studies in which ﬂatus was a secondary end
point only,28, 35, 37, 38 showed no signiﬁcant difference
between seven speciﬁc probiotic treatments and control.
The remaining three studies that evaluated ﬂatus as a
secondary end point reported a signiﬁcant beneﬁcial
effect of three different probiotic treatments29, 33, 39 (one
of which29 also showed no signiﬁcant effect in another
study38). In one of these studies,33 the signiﬁcant effect
was seen at one speciﬁc dose only.
Table 4 | Practical implications of consensus statements for physicians
Grade of evidence
for effect Symptoms/indications Meaning for physicians
High Overall symptoms and abdominal pain in IBS
Prevention or reduction of diarrhoea in
patients receiving antibiotics, including Helicobacter
pylori eradication therapy
Probiotics with supportive evidence for
beneﬁt should be tried
Moderate Overall symptoms in IBS-D
Bowel movements and bloating/
distension in IBS
Probiotics with supportive evidence for
beneﬁt could be tried
Low Overall symptoms in IBS-C Probiotics with supportive evidence for
beneﬁt could be considered
Very low Flatus in IBS*
Diarrhoea in IBS
Currently no evidence to support
use of probiotics
Constipation in IBS is not addressed in this table because consensus was not achieved for this statement.
IBS, irritable bowel syndrome; IBS-C, constipation-predominant IBS; IBS-D, diarrhoea-predominant IBS.
* The grade of evidence was initially deemed to be low (rather than very low) for ﬂatus in IBS, but the statement was revised to
be negative in response to voter feedback during the Delphi process.
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Five studies examined the effect of six different pro-
biotics on ﬂatus in indications other than IBS. In two
studies, no signiﬁcant effects on ﬂatus (primary end
point for one probiotic52; secondary end point for two
other probiotics61) were reported. In three studies, a sig-
niﬁcant beneﬁt of three different probiotic treatments on
ﬂatus (secondary end point) was noted; these studies
were in women with mild digestive symptoms,51 patients
with functional GI symptoms50 and individuals with lac-
tose intolerance undergoing a lactose breath test.53
Constipation
Statement 7: speciﬁc probiotics may help reduce consti-
pation in some patients with IBS. Agreement: 60% (5,
20%; 4, 40%; 3, 30%; 1, 10%; grade of evidence for effect:
low).
Supportive evidence: Two studies of two different pro-
biotics examined treatment of constipation as a second-
ary end point in 156 patients with IBS. One study
(speciﬁcally in patients with IBS-C) reported signiﬁcant
improvements with the speciﬁc probiotic treatment vs.
control for some of the end points (orocaecal transit
time, colonic transit time and urgency), but not others
(stool frequency and consistency, straining during evacu-
ation and feelings of incomplete evacuation).35 The sec-
ond study did not detect any effects of the speciﬁc
probiotic treatment on the frequency of bowel move-
ments and feelings of incomplete evacuation.56
Two studies of three different probiotics examined
constipation in patients with broader FGID. Of these
studies, one61 reported no signiﬁcant effect of two differ-
ent probiotic treatments, and the other study50 did not
report a between-group statistical analysis; however, the
decrease in constipation frequency score was approxi-
mately twofold greater in the probiotic groups than in
the placebo groups.
Bowel habit
Statement 8: speciﬁc probiotics help improve frequency
and/or consistency of bowel movements in some
patients with IBS. Agreement: 70% (6, 10%; 5, 40%; 4,
20%; 3, 20%; 2, 10%; grade of evidence for effect: moder-
ate).
Supportive evidence: Seventeen studies of 14 different
probiotics evaluated bowel habit in 1777 patients with
IBS. Of these, two studies of two different probiotics
evaluated bowel habit as a primary end point, with one
study reporting no difference in GI transit measurements
between the probiotic and placebo groups,38 and one
reporting no signiﬁcant difference in weekly defecation
frequency between the probiotic and placebo groups, but
a signiﬁcant positive effect of the speciﬁc probiotic treat-
ment vs. placebo on the secondary end points of urgency
and feelings of incomplete evacuation.58
Fifteen of the 17 studies in patients with IBS evaluated
bowel habit as a secondary end point only. The main
end points assessed were stool frequency, stool consis-
tency and satisfaction with bowel habits. One or more of
these end points were evaluated in 14 studies, with seven
reporting signiﬁcant beneﬁcial effects of seven different
probiotics,26, 27, 33, 34, 36, 37, 56 six reporting no signiﬁ-
cant effects of ﬁve different probiotics28, 29, 31, 32, 57, 60
(one of which29 showed no signiﬁcant beneﬁt as a pri-
mary end point in another study38) and one reporting a
signiﬁcant negative effect of the speciﬁc probiotic treat-
ment.59 In addition, one study reported signiﬁcant
improvements in the secondary end points of transit
time (see Constipation section) and urgency in patients
with IBS-C, but no signiﬁcant effects on straining and
feelings of incomplete evacuation.35
Four studies of ﬁve different probiotic treatments
assessed bowel habit in indications other than IBS, with
all ﬁve probiotics showing signiﬁcant effects on measures
of bowel habit (see Table 3).50, 51, 54, 62
Diarrhoea
Statement 9: probiotics tested to date do not reduce
diarrhoea in patients with IBS. Agreement: 80% (6, 30%;
5, 30%; 4, 20%; 2, 20%; grade of evidence for effect: very
low).
Supportive evidence: Three studies of three different
probiotics evaluated, as a secondary end point, the treat-
ment of diarrhoea in 152 patients with IBS. Two studies
reported no difference between speciﬁc probiotic treat-
ments and placebo,28, 37 and one study reported a signif-
icant worsening of diarrhoea with the speciﬁc probiotic
treatment compared with placebo.59
Four studies of six different probiotics evaluated diar-
rhoea as a secondary end point in indications other than
IBS. Speciﬁc probiotic treatment had no signiﬁcant effect
on diarrhoea in elderly nursing home residents,54 indi-
viduals with a functional bowel disorder61 and individu-
als with functional GI symptoms.50 The only identiﬁed
study to show a beneﬁcial effect was a study of one
speciﬁc probiotic in patients with lactose intolerance53;
in this study, diarrhoea improved signiﬁcantly in the
probiotic group, but not in the placebo group.
Statement 10: in patients receiving antibiotic therapy,
speciﬁc probiotics are helpful as adjuvant therapy
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to prevent or reduce the duration of associated
diarrhoea. Agreement: 100% (6, 60%; 5, 40%; grade of
evidence for effect: high).
Supportive evidence: Six studies of four different pro-
biotics examined prevention of AAD and/or reduction in
AAD in 1246 patients who received antibiotics. Although
initiated in a hospital setting, these studies were included
because of the relevance of AAD to primary care. Five
studies examined AAD as a primary end point, with four
studies of two different probiotics showing a signiﬁcant
reduction in AAD,40–43 and one underpowered study of
another probiotic showing a nonsigniﬁcant reduction.45
One study assessed AAD as a secondary end point only
and found no difference between the probiotic and pla-
cebo groups.44
Statement 11: in patients receiving H. pylori eradication
therapy, speciﬁc probiotics are helpful as adjuvant
therapy to prevent or reduce the duration/intensity of
associated diarrhoea. Agreement: 100% (6, 60%; 5, 40%;
grade of evidence for effect: high).
Supportive evidence: Four studies, which evaluated ﬁve
different probiotics, had a primary objective to investi-
gate the occurrence of diarrhoea as a side effect of H.
pylori eradication triple therapy in 382 patients. All four
studies reported a signiﬁcant beneﬁt of speciﬁc probiotic
treatments compared with placebo.46–49 However, the
results for two of the probiotic treatments were mixed,
with a signiﬁcant beneﬁt of the speciﬁc probiotic treat-
ment seen after 1 week, but not 2 weeks, in one study,49
and signiﬁcantly fewer days with diarrhoea and shorter
mean duration of diarrhoea episodes, but no signiﬁcant
difference in frequency of diarrhoea episodes, in the pro-
biotic group compared with the placebo group in
another study.48
Health-related quality of life
Statement 12: with speciﬁc probiotics, improvement of
symptoms has been shown to lead to improvement in
some aspects of health-related quality of life. Agree-
ment: 80% (6, 10%; 5, 30%; 4, 40%; 3, 20%; grade of evi-
dence for effect: moderate).
Supportive evidence: Health-related quality of life was
assessed as a primary end point in three studies of three
different probiotics. One study in patients with IBS-C36
reported no signiﬁcant difference between the probiotic
and placebo groups for the change from baseline in the
discomfort dimension score of the Functional Digestive
Disorders Quality of Life (FDDQL) questionnaire (pri-
mary end point); however, the probiotic group had a sig-
niﬁcantly greater proportion of responders for the
discomfort dimension score than the placebo group at
week 3. Another study of the same probiotic was per-
formed in women with minor GI symptoms, and
reported a signiﬁcantly greater improvement in ‘GI
well-being’ (primary end point) in the probiotic group
than in the placebo group.51 The remaining study
assessed two different probiotics in patients with FGID61
and reported no signiﬁcant differences between the pro-
biotic and control groups for the Gastrointestinal Quality
of Life Index (GIQLI) total score and well-being sub-
scales (physical, social and mental; primary end point);
however, the 36-item Short-Form Health Survey (SF-36;
secondary end point) showed signiﬁcant changes in the
probiotic groups for physical functioning and/or ‘role–
physical’ domains, but no signiﬁcant changes in the con-
trol groups.
Twelve studies assessed aspects of health-related qual-
ity of life as secondary end points only. Of these, seven
(evaluating six different probiotics) found no difference
between treatment groups in measures of health-related
quality of life.28, 31–33, 52, 57, 58 The remaining ﬁve stud-
ies (all in patients with IBS) reported signiﬁcant beneﬁts
of ﬁve different probiotic treatments for some aspects of
health-related quality of life.26, 27, 34, 37, 56
Adverse events
Statement 13: probiotics have a favourable safety proﬁle
in patients with a range of lower GI symptoms typically
managed in primary care or general practice. Agree-
ment: 100% (6, 80%; 5, 20%; grade of evidence for effect:
high).
Supportive evidence: Safety data were reported in 28
studies, none of which revealed signiﬁcant treat-
ment-emergent adverse events that were attributed to
probiotic use. Of the 28 studies, 25 reported no relevant
differences in safety between 23 speciﬁc probiotic treat-
ments and placebo.28, 29, 31–34, 36–43, 45–48, 50, 56–58, 60–62
The remaining three studies (each examining a different
probiotic) are summarised below.
In a study of patients with IBS, two patients in the
probiotic group discontinued from the study because of
adverse events (moderate nausea and severe exanthema).
However, the most frequent adverse events (fatigue, pru-
ritus and diarrhoea) occurred equally in the probiotic
and placebo groups.27 In a study of patients with IBS,
one participant had a short stay in hospital for cervico-
brachialgia 2 weeks after the end of the speciﬁc probiotic
treatment; however, there was no organic explanation
and the patient continued in the trial.59 In a study of
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healthy athletes, there was a twofold increase in the
number and duration of mild GI symptoms in the pro-
biotic group compared with the placebo group, although
severity tended to be lower.55
General considerations
Statement 14: speciﬁc probiotics have a role in the man-
agement of some IBS symptoms and can also be used
as an adjunct to conventional treatment. Agreement:
90% (6, 60%; 5, 20%; 4, 10%; 2, 10%; grade of evidence
for effect: NA).
Statement 14 was derived from the evidence collated
during this international consensus and from the clinical
experience of the Consensus Group. It was presented for
voting with the following explanations: for patients with
IBS who are responding positively to conventional ther-
apy, probiotics should be considered as an adjunct rather
than a replacement for conventional treatment; for
patients with IBS who are not responding to conven-
tional therapy, replacement of the ineffective conven-
tional treatment with a probiotic may be considered.
Statement 15: probiotic strains should be selected based
on the patient’s symptoms, the clinical indication and
the available evidence; no probiotic alleviates the full
range of symptoms in IBS. Agreement: 80% (6, 20%; 5,
50%, 4, 10%; 3, 10%; 2, 10%; grade of evidence for effect:
NA).
Statement 15 was based on the observation that some
studies in patients with IBS showed a beneﬁcial effect of
a given probiotic on some symptoms, but not on others.
For example, one study reported that Biﬁdobacterium
biﬁdum MIMBb75 was beneﬁcial for improving global
IBS symptoms, bloating and aspects of health-related
quality of life (physical and mental health), but not for
frequency of bowel movement and feeling of incomplete
bowel evacuation.56 In another study, Biﬁdobacterium
longum subsp. infantis 35624 (1 9 108 CFU once daily)
signiﬁcantly improved all IBS symptoms assessed, except
urgency.33 Studies of multi-strain probiotics provide fur-
ther examples.28, 57, 58
Statement 16: when trying a probiotic therapy for a
chronic GI problem, the product should be taken for
1 month; dose selection should be based on available
evidence and manufacturers’ recommendations. Agree-
ment: 80% (6, 30%; 5, 40%; 4, 10%; 2, 20%; grade of
evidence for effect: NA).
Statement 16 was based on the observation that the
treatment duration was at least 4 weeks in most studies
(21/24) that examined probiotics for the treatment of
chronic GI problems.
DISCUSSION
This is the ﬁrst practical consensus on the role of pro-
biotics in the management of the full range of lower GI
symptoms in adults consulting clinicians in a pragmatic
setting (particularly in primary care). The outcome of this
consensus (summarised in Tables 3 and 4) is relevant to
both primary care physicians and gastroenterologists, and
is important because patients as well as the general public
are becoming increasingly aware of probiotics as a result
of considerable media interest and intensive advertising
campaigns. Consequently, there is a need for physicians
to be in a position to provide advice on whether probiot-
ics might be helpful for patients with speciﬁc lower GI
symptoms/problems, and, if so, which ones might be
appropriate to recommend. What is evident is that there
is no clear, simple guidance possible and that research
linking speciﬁc probiotics with particular symptoms or
problems is complex to interpret, partly because of the
widespread types of studies and end points. However, our
research conﬁrms that there is positive evidence for the
role of probiotics in lower GI problems.
Consensus ﬁndings in comparison with other
research
A strong consensus was reached on the positive role of
probiotics in the prevention of AAD or diarrhoea associ-
ated with H. pylori eradication therapy. Although the
strain-/formulation-speciﬁc properties of different probi-
otics mean that meta-analyses of probiotics should be
interpreted with caution, our ﬁndings are consistent with
several previous meta-analyses,63–67 and the potential of
probiotics to reduce side effects is also noted in the
Maastricht IV/Florence consensus report on the manage-
ment of H. pylori infection.68 Furthermore, our ﬁnding is
consistent with the proposed role of probiotics in main-
taining the gut microbiota,69 which are typically dis-
turbed during oral antibiotic treatment. However, the
current consensus does not support a role for probiotics
in the treatment of diarrhoea in adults with IBS. The
role of probiotics in the prevention of traveller’s diar-
rhoea is also a topic of interest,70, 71 but was not
addressed in any of the studies eligible for the current
analysis.
The Consensus Group concluded, with a high level of
evidence, that speciﬁc probiotics help reduce overall
symptom burden and abdominal pain in IBS (Statements
1 and 4: 100% agreement among voters), consistent with
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previous meta-analyses and reviews.2, 8, 10 There was a
moderate level of evidence, with 70% agreement, for a
role of speciﬁc probiotics in reducing bloating and
improving the frequency and/or consistency of bowel
movements in IBS (Statements 5 and 8). The level of evi-
dence was also moderate for a role of probiotics in
improving some aspects of health-related quality of life
(Statement 12: 80% agreement); there is a need for more
research on the effects of probiotics on health-related
quality of life, because this has clear implications for the
day-to-day functioning of the patient.
There was a low level of evidence for a role of speciﬁc
probiotics in reducing constipation [Statement 7: 60%
agreement (no consensus)] and for the statement that
probiotics tested to date do not reduce ﬂatus in patients
with IBS (Statement 6: 90% agreement). An overview of
meta-analyses in IBS showed a similar trend, with more
supportive evidence available for overall symptom bur-
den and abdominal pain than for ﬂatus.8 Nevertheless, a
meta-analysis of studies in adults with IBS did report a
signiﬁcant reduction in ﬂatus with probiotic treatment.72
The lack of consensus on the role of probiotics in the
management of constipation is consistent with the
World Gastroenterology Organisation guideline on pre-
biotics and probiotics, which recommends certain pre-
biotics, but not probiotics, for the treatment of
constipation.10 The grade of evidence and level of agree-
ment were higher for bowel habit than for constipation;
a possible explanation is that improvement in individual
measures of function might be easier to achieve (or mea-
sure) than improvement in multiple facets of a GI prob-
lem. However, other confounding factors may play a
role: besides a potential gender effect, biﬁdobacteria,
attaining their highest counts in the colon, are more
likely to have an effect on the colonic transit time than
lactobacilli, which occur mainly in the small bowel.
Oral probiotics had a favourable safety proﬁle in the
included studies overall; the majority of the studies
found no differences in safety between probiotic and pla-
cebo, and none of the studies identiﬁed signiﬁcant
adverse events attributed to probiotic use. The statement
on the safety of probiotics achieved the highest degree of
consensus. However, safety should not be generalised to
untested situations, including other probiotics and differ-
ent modes of administration, such as delivery by enteral
tube.73 In addition, their use in certain patient groups,
such as those who are immuno-compromised, needs to
be considered on a case-by-case basis – at present, there
are few data on the safety of probiotics in such patients.
Immune compromise (including a debilitated state or
malignancy) has been identiﬁed as a risk factor for rare
cases of bacteraemia or fungaemia in patients taking
certain probiotics (most commonly Saccharomyces
boulardii).74–76
Strengths and limitations
Suboptimal trial design has been highlighted as an
important issue in studies of probiotics.77 To address
this, we applied strict quality criteria in the selection of
papers: only randomised, placebo-controlled clinical
trials of probiotics that had suitable follow-up were
included in the analysis. However, a limitation of the
current consensus, similar to any systematic review, is
the potential for publication bias – inconclusive or nega-
tive results are less likely to be published than positive
results. Furthermore, studies designed to assess one end
point can show positive effects on other end points by
chance. We have therefore only included studies with a
sample size calculation and we have distinguished
between results that were assessed as primary and sec-
ondary end points to limit the inﬂuence of chance ﬁnd-
ings in secondary end points. Challenges identiﬁed by
the Consensus Group during the voting process included
the small number of high-quality studies, small study
populations and diverse results, with some members not-
ing that the evidence was insufﬁcient to fully support
Statements 5 and 8, and that there is currently insufﬁ-
cient evidence to personalise choices in probiotic treat-
ment (in response to Statement 15). The Consensus
Group included representatives from many European
countries, but the relevance of the statements to all
European primary care/gastroenterology settings cannot
be determined.
Factors determining the response to treatment include
probiotic strain(s), dose and mode of administration,
health status of the patient, diet and concomitant medi-
cations (e.g. antibiotics and antacids). The variable
results noted across some of the studies included in our
analysis could have been affected by any of these factors,
as well as the different patient groups enrolled in the
studies and different levels of placebo response. Further-
more, this consensus focused on adults, and the state-
ments cannot be extended to children. Additional points
to consider are that probiotic research is evolving rap-
idly, and that the current statements reﬂect physicians’,
rather than patients’, perspectives. Many patients have
an interest in probiotics and their potential to reduce
their symptoms,78, 79 and may take probiotics (or
products incorrectly identiﬁed as probiotics) before con-
sulting their physician. Therefore, educational materials
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for the general public are also needed to improve under-
standing and to ensure appropriate use of probiotics (see
the consumer guidelines of the International Scientiﬁc
Association for Probiotics and Prebiotics for an exam-
ple15, 80). To address these points, the ESPCG intends to
update this consensus publication with new research and
input from patient groups in 3 years.
Most of the studies eligible for inclusion in this con-
sensus focused on IBS or AAD; only a small subset of
the studies examined probiotics in healthy individuals or
patients with lactose malabsorption, other functional GI
problems or mild GI symptoms, and therefore speciﬁc
statements were not prepared for these groups. Never-
theless, this small subset of studies was still included
alongside the statements in Table 3 for completeness.
The prophylactic application of probiotics is a potentially
interesting area for future research, although it will be
challenging in terms of study design.
CONCLUSIONS AND CLINICAL IMPLICATIONS
The practical clinical implications of the consensus state-
ments are summarised for each grade of evidence in
Table 4. It should be noted that effects are strain-/
formulation-speciﬁc and cannot be extrapolated from
one probiotic to another. Furthermore, speciﬁc probiotics
will have different effects in different patients; a probiotic
that does not work in one indication may have evidence
supporting a beneﬁcial effect in a different indication or
for a different symptom. When trying a probiotic ther-
apy for a chronic GI problem, it is critically important
that the product is taken in adequate doses on a regular
basis (e.g. just before a meal) for a reasonable period of
time, which should be at least a month, unless it cannot
be tolerated for any reason. Regular consumption is
important because probiotic strains are transient and will
generally be washed out within days, although strain-spe-
ciﬁc differences occur, for example, linked to the produc-
tion of pili81, 82 or mucus-binding proteins83 by the
probiotic bacteria.
The need for objective, evidence-based guidance on
the role of probiotics is becoming increasingly important
as public awareness of probiotics grows. This consensus
is intended as a practical reference to help physicians
make appropriate, evidence-based recommendations to
patients who might beneﬁt from probiotic treatment.
Overall, the randomised, placebo-controlled trials
included in our analysis support, with a high evidence
level, a role for speciﬁc probiotics in the management of
overall symptoms and abdominal pain in patients with
IBS, and for preventing or reducing diarrhoea in patients
receiving antibiotics or H. pylori eradication triple ther-
apy. The trials support, with a moderate evidence level, a
role for speciﬁc probiotics in managing overall symptoms
in patients with IBS-D; improving bowel movements and
bloating/distension in patients with IBS; and improving
some aspects of health-related quality of life.
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